EPHA3 and central nervous system cancer: Notably, expression was highest in the U251CL and U87 lines, while relatively lower levels were observed in U118, A172, SU-DIPG36GL, SU-DIPG4, SU-DIPG13, SU-DIPG33, underscoring the potential for EphA3-targeted CAR therapies in diverse glioma contexts.